Patents by Inventor Luke Burman

Luke Burman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES
    Publication number: 20240092917
    Abstract: Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
    Type: Application
    Filed: September 28, 2023
    Publication date: March 21, 2024
    Inventors: Luke BURMAN, Yeeting CHONG, Leslie Ann GREENE, David KING, Zhiwen XU, Ryan Andrew ADAMS
  • Therapeutic compositions comprising anti-NRP2 antibodies
    Patent number: 11807687
    Abstract: Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 7, 2023
    Assignee: aTyr Pharma, Inc.
    Inventors: Luke Burman, Yeeting Chong, Leslie Ann Greene, David King, Zhiwen Xu, Ryan Andrew Adams
  • Compositions and methods comprising anti-NRP2 antibodies
    Patent number: 11505610
    Abstract: Provided are antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, for example, human histidyl-tRNA synthetase (HRS), and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: November 22, 2022
    Assignee: aTyr Pharma, Inc.
    Inventors: Luke Burman, Yee Ting (Esther) Chong, Yanyan Geng, Leslie Nangle Greene, Kristina Hamel, David King, Ann Menefee, Kaitlyn Rauch, Zhiwen Xu, Liting Zhai
  • COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES
    Publication number: 20210163606
    Abstract: Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
    Type: Application
    Filed: October 2, 2020
    Publication date: June 3, 2021
    Inventors: Luke BURMAN, Yeeting CHONG, Leslie Ann GREENE, David KING, Zhiwen XU, Ryan Andrew ADAMS
  • COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES
    Publication number: 20190309076
    Abstract: Provided are antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, for example, human histidyl-tRNA synthetase (HRS), and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases
    Type: Application
    Filed: April 5, 2019
    Publication date: October 10, 2019
    Inventors: Luke BURMAN, Yee Ting (Esther) CHONG, Yanyan GENG, Leslie Nangle GREENE, Kristina HAMEL, David KING, Ann MENEFEE, Kaitlyn RAUCH, Zhiwen XU, Liting ZHAI
  • ANTI-HRS ANTIBODIES AND COMBINATON THERAPIES FOR TREATING CANCERS
    Publication number: 20180282402
    Abstract: Provided are antibodies that specifically bind to human histidyl-tRNA synthetase and related therapeutic compositions and methods for treating cancer, including as standalone therapies or in combination with cancer immunotherapies, for example, immune checkpoint modulators such as PD-1 inhibitors.
    Type: Application
    Filed: November 30, 2017
    Publication date: October 4, 2018
    Inventors: Ryan Andrew Adams, Luke Burman, Yeeting Chong, David King, John D. Mendlein, Leslie Nangle Greene, Kathleen Ogilvie, Kaitlyn Rauch
  • Ribosomal polynucleotides and related expression systems
    Patent number: 9359616
    Abstract: Provided herein is a synthetic or isolated polynucleotide encoding a mammalian 18S rRNA that is resistant to pactamycin. The pactamycin-resistance is conferred by one or more single residue substitutions in the 18S rRNA sequence; a fragment thereof harboring said substitutions; a complementary sequence thereto; or a substantially identical sequence of the foregoing. Related systems, methods and kits are also described.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: June 7, 2016
    Assignee: The Scripps Research Institute
    Inventors: Vincent P. Mauro, Luke Burman, Gerald M. Edelman
  • Ribosomal Polynucleotides and Related Expression Systems
    Publication number: 20130309682
    Abstract: Provided herein is a synthetic or isolated polynucleotide encoding a mammalian 18S rRNA that is resistant to pactamycin. The pactamycin-resistance is conferred by one or more single residue substitutions in the 18S rRNA sequence; a fragment thereof harboring said substitutions; a complementary sequence thereto; or a substantially identical sequence of the foregoing. Related systems, methods and kits are also described.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 21, 2013
    Inventors: Vincent P. Mauro, Luke Burman, Gerald M. Edelman